Socomed Pharma Private Limited

Socomed Pharma Private Limited, incorporated on April 24, 2008, is a private limited company based in Mumbai, Maharashtra, India. The company is classified under the Corporate Identification Number (CIN) U24233MH2008PTC181516 and is registered with the Registrar of Companies, Mumbai. Its authorized share capital is ₹5,000,000, with a paid-up capital of ₹4,861,500. The registered office is located at ORM B-Wing, Unit No 112, Upper Gr. Survey No. 169, Aarey Milk Colony, Near Unit No. 26, Goregaon (E), Mumbai, Maharashtra 400065, India.

Socomed Pharma specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has a workforce of approximately 30 employees as of October 11, 2025. The official website is www.socomedpharma.com.

Socomed Pharma operates manufacturing facilities in Mumbai, Maharashtra, India. The company specializes in producing a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the capacities and certifications of these facilities are not publicly disclosed.

The company's board of directors includes:

• Aasif Amirkhan Dange
• Director since December 13, 2011.

• Bakhtawar Mairaj Aasif Dange
• Director since October 1, 2021.

Specific information regarding the CEO, CFO, and other key executives is not publicly available.

Socomed Pharma's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not publicly documented. The company has not disclosed any regulatory filings, approvals, or market access statuses in these regions. This lack of information suggests that Socomed Pharma may not have significant market penetration in these regulated markets.

Socomed Pharma's activities in emerging markets, including Africa, Latin America, and Southeast Asia, are not publicly detailed. The company has not disclosed any information regarding WHO prequalification or other certifications that would enable access to these markets. This absence of information indicates that Socomed Pharma may not have established a significant presence in these regions.

Socomed Pharma's export data indicates a concentration in specific therapeutic categories, with 49.0% of exports in Respiratory & OTC, 40.2% in Analgesics & Antipyretics, and 9.6% in Antihistamines & Allergy. The company's top five products—Caffeine, Paracetamol, Diclofenac, Phenylephrine, and Chlorpheniramine—account for 98.9% of its total export value. This high portfolio concentration suggests a focused geographic strategy, potentially limiting exposure to market diversification risks.

Specific details regarding Socomed Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company has not disclosed any information regarding its status with the U.S. Food and Drug Administration (FDA), indicating a lack of market presence or regulatory approvals in the United States.

Socomed Pharma has not publicly disclosed any certifications such as WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The absence of this information suggests that the company may not have obtained these certifications, which are often required for market access in certain regions.

Socomed Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India. The company has also obtained approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export activities. Specific details regarding these licenses and approvals are not publicly disclosed.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Socomed Pharma. The absence of such information suggests that the company has not faced significant regulatory actions in the public domain.

Socomed Pharma operates in the competitive pharmaceutical industry, focusing on finished pharmaceutical formulations. While specific competitors are not identified, the company's export data indicates a strong presence in the Respiratory & OTC and Analgesics & Antipyretics categories. The high concentration of exports in a few products suggests that Socomed Pharma may face competition from other manufacturers specializing in these therapeutic areas.

Socomed Pharma's key differentiators include its specialization in finished pharmaceutical formulations and a focused product portfolio. The company's emphasis on specific therapeutic categories may allow for expertise and efficiency in production. However, the high concentration in a few products could also pose risks related to market fluctuations and demand variability.

Socomed Pharma's current strategic direction appears to be focused on manufacturing and exporting finished pharmaceutical formulations, particularly in the Respiratory & OTC and Analgesics & Antipyretics categories. The company's future outlook may involve expanding its product portfolio, obtaining additional regulatory certifications, and exploring new markets to diversify its revenue streams and reduce concentration risks.

Socomed Pharma has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $25.0 million USD and 1,131 shipments across six products. The company's reliability is indicated by its established presence in specific therapeutic categories and a focused product portfolio. However, the high concentration in a few products suggests that Socomed Pharma may need to diversify its offerings to mitigate potential risks associated with market demand fluctuations.

Importers should verify the following certifications when considering Socomed Pharma as a supplier:

• FDA Facility Registration: To confirm compliance with U.S. regulations. Verification can be done through the FDA's official website.

• WHO-GMP Certification: To ensure adherence to World Health Organization standards. Verification can be done through the WHO's official website.

• EU GMP Certification: To confirm compliance with European Union manufacturing standards. Verification can be done through the European Medicines Agency's official website.

• ISO Certifications: To ensure quality management systems are in place. Verification can be done through the International Organization for Standardization's official website.

When conducting due diligence on Socomed Pharma, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Financial Health: Review the company's financial statements and credit history.

• Evaluate Manufacturing Capabilities: Inspect manufacturing facilities for compliance with quality standards.

• Review Export Records: Analyze export data to assess consistency and reliability.

• Check for Legal Compliance: Ensure the company adheres to all relevant laws and regulations.

Red flags to watch for include discrepancies in certification validity, financial instability, and non-compliance with regulatory standards. Recommended pre-order checks involve obtaining recent inspection reports, verifying product quality through third-party testing, and assessing the company's reputation in the industry.